ReviewCancer reports (Hoboken, N.J.)2024
Prostate Cancer: A Review of Genetics, Current Biomarkers and Personalised Treatments.
Review in Cancer reports (Hoboken, N.J.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Research on potential biomarkers of prostate cancer in Latin America and the Caribbean: a scoping review.Frontiers in oncology · 2026Pooled it
- Immunohistochemical and Transcriptomic Assessment of Cytochrome 2J2 in Prostate and Renal Cancer.Cancers · 2026Article
- Stratified Analysis of Patients Within the PSA Gray Zone (4-10 ng/mL) and Its Clinical Application Value: Development of a Predictive Model for Clinically Significant Prostate Cancer Using Quantitative Indicators of PSA, ADC, and Relative T2 Value.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- Development and Characterization of the PSMA-Expressing CT26-PSMA Cell Line as a Rapid Preclinical Platform forInternational journal of molecular sciences · 2026Article
- Article
- The association between diet-exercise patterns and self-reported prostate cancer: A cross-sectional NHANES study.Medicine · 2026Article
- Coupled Cell-Intrinsic and Microenvironmental Heterogeneity Drives Divergent Trajectories in Castration-Resistant Prostate Cancer.bioRxiv : the preprint server for biology · 2026Article
- Efficacy of Modified Extraperitoneal Laparoscopic Intrafascial Radical Prostatectomy in Prostate Cancer and Analysis of Factors Influencing Postoperative Urinary Continence Recovery.APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2026Article
- Integrative advances in biomarker-driven prostate cancer management from genomic discovery to precision oncology.Discover oncology · 2026Review
- Long-Term Outcomes of Low-Dose-Rate Brachytherapy in Localized Prostate Cancer: A 17-Year Retrospective Analysis of a Single-Center Portuguese Cohort.Journal of clinical medicine · 2026Article
- Integrative Whole-Genome and Epigenome Profiling of cfDNA in Familial Prostate Cancer: Insights from a Pilot Study.Biomedicines · 2026Article
- Review
- Mechanistic insights and clinical implications of RNA-binding proteins in prostate cancer.Discover oncology · 2026Review
- Role of HOXA transcript antisense RNA myeloid-specific 1 in cancer (Review).Oncology letters · 2026Review
- Article
- Prostate Cancer, JAK/STAT3 Dysregulation, and Flavonoids: Is There a Possible Link?International journal of molecular sciences · 2026Review
- Prognostic Value of the Postoperative Advanced Lung Cancer Inflammation Index in Patients with Prostate Cancer Undergoing Radical Prostatectomy.Journal of inflammation research · 2026Article
- Development and validation of a combined diagnostic model for prostate cancer integrating MRI parameters with p504s, CK5/6, and Ki-67 expression.Open life sciences · 2026Article
- Comprehensive Biochemical Insights into Prostate-Specific Antigen: From Biomarker to Functional Mediator in Prostate Cancer Pathophysiology.Anti-cancer agents in medicinal chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer is the second leading cause of cancer deaths in men, second only to lung cancer. Despite this, diagnosis and prognosis methods remain limited, with effective treatments being few and far between. Traditionally, prostate cancer is initially tested for through a prostate serum antigen (PSA) test and a digital rectum examination (DRE), followed by confirmation through an invasive prostate biopsy. The DRE and biopsy are uncomfortable for the patient, so less invasive, accurate diagnostic tools are needed. Current diagnostic tools, along with genes that hold possible biomarker uses in diagnosis, prognosis and indications for personalised treatment plans, were reviewed in this article. RECENT
findingsSeveral genes from multiple families have been identified as possible biomarkers for disease, including those from the MYC and ETS families, as well as several tumour suppressor genes, Androgen Receptor signalling genes and DNA repair genes. There have also been advances in diagnostic tools, including MRI-targeted and liquid biopsies. Several personalised treatments have been developed over the years, including those that target metabolism-driven prostate cancer or those that target inflammation-driven cancer.
conclusionSeveral advances have been made in prostate cancer diagnosis and treatment, but the disease still grows year by year, leading to more and more deaths annually. This calls for even more research into this disease, allowing for better diagnosis and treatment methods and a better chance of patient survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.